Three-Dimensional Bioprinted Controlled Release Scaffold Containing Mesenchymal Stem/Stromal Lyosecretome for Bone Regeneration: Sterile Manufacturing and In Vitro Biological Efficacy.

3D coprinting Lyosecretome MSC extracellular vesicles MSC secretome alginate hydrogel bone regenerative medicine bone tissue engineering mesenchymal stem cells poly(ε-caprolactone)

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
03 May 2022
Historique:
received: 14 04 2022
revised: 27 04 2022
accepted: 02 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

Recently, 3D-printed scaffolds for the controlled release of mesenchymal stem cell (MSC) freeze-dried secretome (Lyosecretome) have been proposed to enhance scaffold osteoinduction and osteoconduction; coprinting of poly(ε-caprolactone) (PCL) with alginate hydrogels allows adequate mechanical strength to be combined with the modulable kinetics of the active principle release. This study represents the feasibility study for the sterile production of coprinted scaffolds and the proof of concept for their in vitro biological efficacy. Sterile scaffolds were obtained, and Lyosecretome enhanced their colonization by MSCs, sustaining differentiation towards the bone line in an osteogenic medium. Indeed, after 14 days, the amount of mineralized matrix detected by alizarin red was significantly higher for the Lyosecretome scaffolds. The amount of osteocalcin, a specific bone matrix protein, was significantly higher at all the times considered (14 and 28 days) for the Lyosecretome scaffolds. Confocal microscopy further confirmed such results, demonstrating improved osteogenesis with the Lyosecretome scaffolds after 14 and 28 days. Overall, these results prove the role of MSC secretome, coprinted in PCL/alginate scaffolds, in inducing bone regeneration; sterile scaffolds containing MSC secretome are now available for in vivo pre-clinical tests of bone regeneration.

Identifiants

pubmed: 35625800
pii: biomedicines10051063
doi: 10.3390/biomedicines10051063
pmc: PMC9138797
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Interreg V-A Italy-Switzerland 2014-2020
ID : ATEx-Advanced Therapies Experiences. Project ID 637541.

Références

JBJS Rev. 2020 Apr;8(4):e0204
pubmed: 32539264
Adv Healthc Mater. 2018 Jan;7(1):
pubmed: 29193879
Int J Biol Macromol. 2021 Apr 30;177:578-588
pubmed: 33617905
EBioMedicine. 2016 Oct;12:43-54
pubmed: 27693103
Front Endocrinol (Lausanne). 2019 Jan 10;9:794
pubmed: 30687236
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
J Mater Chem B. 2021 Jul 14;9(27):5385-5413
pubmed: 34124724
Biotechnol Appl Biochem. 2007 Feb;46(Pt 2):73-84
pubmed: 17227284
Biomaterials. 2006 Jun;27(18):3413-31
pubmed: 16504284
Eur Spine J. 2001 Oct;10 Suppl 2:S96-101
pubmed: 11716023
Science. 1993 May 14;260(5110):920-6
pubmed: 8493529
Mol Pharm. 2021 Apr 5;18(4):1677-1689
pubmed: 33760625
Int J Mol Sci. 2021 Aug 06;22(16):
pubmed: 34445150
Bone. 2016 Jan;82:42-9
pubmed: 26055108
Int J Bioprint. 2018 Jul 03;4(2):151
pubmed: 33102923
Bioengineering (Basel). 2019 Dec 13;6(4):
pubmed: 31847117
Nat Mater. 2005 Jul;4(7):518-24
pubmed: 16003400
Int J Mol Sci. 2021 Apr 14;22(8):
pubmed: 33920046
J Orthop Surg Res. 2014 Mar 17;9(1):18
pubmed: 24628910
Mol Biotechnol. 2018 Jul;60(7):506-532
pubmed: 29761314
Pharmaceutics. 2021 Apr 08;13(4):
pubmed: 33918073
Macromol Biosci. 2004 Aug 9;4(8):743-65
pubmed: 15468269
Materials (Basel). 2018 Nov 06;11(11):
pubmed: 30404222
Biofabrication. 2021 Apr 08;13(3):
pubmed: 33662949
Adv Drug Deliv Rev. 2021 Aug;175:113775
pubmed: 33872693
Int J Pharm. 2017 Jul 15;527(1-2):161-170
pubmed: 28461267
Biomaterials. 2007 Jun;28(18):2810-20
pubmed: 17367852
PLoS Genet. 2020 Jun 2;16(6):e1008714
pubmed: 32484816
Cell Biochem Biophys. 2015 Jul;72(3):777-82
pubmed: 25663505

Auteurs

Elia Bari (E)

Department of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2/3, 28100 Novara, Italy.

Franca Scocozza (F)

Department of Civil Engineering and Architecture, University of Pavia, Via Ferrata 3, 27100 Pavia, Italy.
P4P S.r.l., Via Scapolla 12, 27100 Pavia, Italy.

Sara Perteghella (S)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.
PharmaExceed S.r.l., Piazza Castello 19, 27100 Pavia, Italy.

Lorena Segale (L)

Department of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2/3, 28100 Novara, Italy.

Marzio Sorlini (M)

PharmaExceed S.r.l., Piazza Castello 19, 27100 Pavia, Italy.
Department of Innovative Technologies, University of Applied Sciences and Arts of Southern Switzerland, SUPSI, Lugano University Centre, Campus Est, Via la Santa 1, CH-6962 Viganello, Switzerland.

Ferdinando Auricchio (F)

Department of Civil Engineering and Architecture, University of Pavia, Via Ferrata 3, 27100 Pavia, Italy.
P4P S.r.l., Via Scapolla 12, 27100 Pavia, Italy.

Michele Conti (M)

Department of Civil Engineering and Architecture, University of Pavia, Via Ferrata 3, 27100 Pavia, Italy.
P4P S.r.l., Via Scapolla 12, 27100 Pavia, Italy.

Maria Luisa Torre (ML)

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.
PharmaExceed S.r.l., Piazza Castello 19, 27100 Pavia, Italy.

Classifications MeSH